EICHORCondition: Intracranial Atherosclerosis · Sponsor: Medos International SARL
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to evaluate the safety and effectiveness of CERENOVUS ENTERPRISE 2 intracranial stent implantation in treatment of participants with severe symptomatic intracranial atherosclerotic stenosis.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital, Capital Medical University | Beijing, China | — |
| West China Hospital of Sichuan University | Chengdu, China | — |
| Haikou People's Hospital | Haikou, China | — |
| First Affiliated Hospital, Harbin Medical University | Harbin, China | — |
| Central Hospital Affiliated to Shandong First Medical University (Jinan Central Hospital) | Jinan, China | — |
| Qilu Hospital of Shandong University | Jinan, China | — |
| Shandong Provincial Hospital | Jinan, China | — |
| Nanjing Drum Tower Hospital | Nanjing, China | — |
| Ningbo First Hospital | Ningbo, China | — |
| Huashan Hospital Fudan University | Shanghai, China | — |
| Wenzhou Central Hospital | Wenzhou, China | — |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an, China | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05316311